Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes
- 30 June 2007
- journal article
- review article
- Published by Elsevier BV in Biotechnology Advances
- Vol. 25 (3), 325-331
- https://doi.org/10.1016/j.biotechadv.2007.01.007
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringesKidney International, 2005
- Silicone Oil Induced Aggregation of ProteinsJournal of Pharmaceutical Sciences, 2005
- Characterizing biological products and assessing comparability following manufacturing changesNature Biotechnology, 2004
- Plasticizers, antioxidants, and other contaminants found in air delivered by PVC tubing used in respiratory therapyBiomedical Chromatography, 2003
- Chromatographic separation of recombinant human erythropoietin isoformsJournal of Chromatography A, 1997
- Rapid profiling of carbohydrate glycoforms in monoclonal antibodies using MALDI/TOF mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 1995
- Tryptic Map Variation of Erythropoietin Resulting from Carboxypeptidase B-Like ActivityJournal of Liquid Chromatography, 1994
- Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide MappingPharmaceutical Research, 1992
- Demonstration of Insulin Transformation Products in Insulin Vials by High-Performance Liquid ChromatographyDiabetes Care, 1991
- Survival of recombinant erythropoietin in the circulation: the role of carbohydratesBlood, 1989